# Beta Bionics Inc. (BBNX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Medical Devices & Supplies. Price $15.10, market value $821 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Beta Bionics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 6.5×**. Each dollar of revenue is priced at 6.5×.
- **Price / book: 2.0×**. The shares trade at 2.0× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -8.0%** (5-yr avg -4.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 58.6%**. Beta Bionics Inc. keeps 58.6% of revenue after the direct cost of what it sells.
- **Operating margin: -72.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -73.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -25.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: -25.3%**. Each dollar of assets produces -25.3% of profit.

## Growth
- **Revenue growth (1 yr): 53.9%**. Revenue grew 53.9% over the last year.
- **EPS growth (1 yr): 79.0%**. Earnings per share rose 79.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 8.66** (quick 8.66). Current assets cover the next year's liabilities 8.66 times.
- **Altman Z-score: 13.65**. A Z-score of 13.65 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Beta Bionics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (14 analysts). 14 analysts cover Beta Bionics Inc.; the consensus is buy, with an average price target of $25.10 (+66% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -41.6%** (YTD -47.8%, 3-mo 19.1%). The shares are down 41.6% over twelve months including dividends.
- **From 52-week high: -53.8%** (71.6% above the low). Trading 54% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 38**. An RSI of 38 is neutral.
- **Beta (1 yr): 1.38** (volatility 83%). Beta of 1.38 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BBNX · Page: https://foliofundamentals.com/stocks/bbnx

Not investment advice.